Castle Biosciences (NASDAQ:CSTL) Insider Sells $20,380.36 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 509 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $40.04, for a total transaction of $20,380.36. Following the sale, the insider owned 34,360 shares of the company’s stock, valued at $1,375,774.40. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Castle Biosciences Stock Performance

Shares of CSTL stock traded down $0.16 during trading hours on Friday, hitting $39.44. 357,875 shares of the company were exchanged, compared to its average volume of 454,994. The firm has a fifty day simple moving average of $32.49 and a 200 day simple moving average of $24.44. The company has a current ratio of 6.47, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $40.61. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -87.64 and a beta of 1.14.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.32. The business had revenue of $80.55 million during the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. Research analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Institutional Trading of Castle Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tudor Investment Corp ET AL boosted its holdings in shares of Castle Biosciences by 11.7% during the third quarter. Tudor Investment Corp ET AL now owns 85,435 shares of the company’s stock worth $1,945,000 after purchasing an additional 8,981 shares during the period. Summit Partners Public Asset Management LLC bought a new position in Castle Biosciences during the 3rd quarter valued at approximately $9,108,000. Qube Research & Technologies Ltd raised its position in Castle Biosciences by 14.8% during the 3rd quarter. Qube Research & Technologies Ltd now owns 220,961 shares of the company’s stock valued at $5,031,000 after purchasing an additional 28,408 shares during the last quarter. Parkman Healthcare Partners LLC lifted its holdings in Castle Biosciences by 35.0% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 475,568 shares of the company’s stock worth $10,829,000 after buying an additional 123,306 shares during the period. Finally, Millennium Management LLC grew its position in shares of Castle Biosciences by 34.2% in the 3rd quarter. Millennium Management LLC now owns 575,089 shares of the company’s stock worth $13,095,000 after buying an additional 146,692 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

CSTL has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday. BTIG Research upped their price target on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Robert W. Baird raised their price objective on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Zacks Research upgraded shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $37.00 target price on shares of Castle Biosciences in a research report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.14.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.